Resource Summary Report

Generated by RRID on Aug 31, 2026

MDA-MB-436

RRID:CVCL_0623
Type: Cell Line

Proper Citation

RRID:CVCL_0623

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0623

Proper Citation: RRID:CVCL_0623

Description: Cell line MDA-MB-436 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: PMID:730202, PMID:1961733, PMID:3518877, PMID:7272986, PMID:9288768, PMID:9823299, PMID:10862037, PMID:10969801, PMID:11343771, PMID:15677628, PMID:16397213, PMID:16541312, PMID:17157791, PMID:18516279, PMID:19582160, PMID:19593635, PMID:21778573, PMID:22460905, PMID:22585861, PMID:23151021, PMID:23601657, PMID:24094812, PMID:24162158, PMID:24176112, PMID:25485619, PMID:25877200, PMID:25892236, PMID:26589293, PMID:27397505, PMID:28196595, PMID:28287265, PMID:28889351, PMID:29273624, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-436

Synonyms: MDA_MB_436, MDA MB 436, MDA-Mb-436, MDA-MB436, MDAMB436, MDA-436, MDA436, MB436, MD Anderson-Metastatic Breast-436

Cross References: BTO:BTO_0001568, CLO:CLO_0007639, EFO:EFO_0001214, CLDB:cl7218, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-130, BioGRID_ORCS_Cell_line:553, BioSample:SAMN03471588, BioSample:SAMN03472712, BioSample:SAMN10987901, cancercelllines:CVCL_0623, CCRID:1101HUM-PUMC000352, CCRID:3101HUMTCHu184, Cell_Model_Passport:SIDM00629, ChEMBL-Cells:CHEMBL4295382, ChEMBL-Targets:CHEMBL4296465, CLS:300278, Cosmic:809240, Cosmic:871156, Cosmic:897425, Cosmic:904382, Cosmic:934528, Cosmic:949191, Cosmic:979718, Cosmic:1010926, Cosmic:1017165, Cosmic:1027055, Cosmic:1044206, Cosmic:1044222, Cosmic:1046957, Cosmic:1071902, Cosmic:1176604, Cosmic:1287923, Cosmic:1289400, Cosmic:1309008, Cosmic:1434955, Cosmic:1609474, Cosmic:2009513, Cosmic:2164998, Cosmic:2361353, Cosmic-CLP:1240172, DepMap:ACH-000573, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240172, GEO:GSM115100, GEO:GSM149985, GEO:GSM149993, GEO:GSM150001, GEO:GSM217589, GEO:GSM344354, GEO:GSM344404, GEO:GSM350541, GEO:GSM421878, GEO:GSM783954, GEO:GSM844600, GEO:GSM844601, GEO:GSM845397, GEO:GSM847416, GEO:GSM847496, GEO:GSM887299, GEO:GSM888374, GEO:GSM1008909, GEO:GSM1053725, GEO:GSM1172982, GEO:GSM1214583, GEO:GSM1238135, GEO:GSM1374658, GEO:GSM1374659, GEO:GSM1401656, GEO:GSM1670085, GEO:GSM2258866, GEO:GSM2258867, GEO:GSM2258868, GEO:GSM2258869, GEO:GSM2258870, GEO:GSM2258871, GEO:GSM2258872, GEO:GSM2258873, GEO:GSM2258874, GEO:GSM2258875, GEO:GSM2258876, GEO:GSM2258877, GEO:GSM2258878, GEO:GSM2258879, GEO:GSM2258880, GEO:GSM2258881, GEO:GSM2258882, GEO:GSM2258883, GEO:GSM2258938, GEO:GSM2258939, GEO:GSM2258940, GEO:GSM3161722, GEO:GSM3161723, IARC_TP53:18371, IARC_TP53:26994, ICLC:HTL11005, IZSLER:BS TCL 246, LiGeA:CCLE_254, LINCS_HMS:50333, LINCS_LDP:LCL-1470, PharmacoDB:MDAMB436_905_2019, PRIDE:PXD005292, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_0623, PubChem_Cell_line:CVCL_0623, SLKBase:3609, TOKU-E:2399, Wikidata:Q54904639

ID: CVCL_0623

Record Creation Time: 20220427T220756+0000

Record Last Update: 20260829T234602+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-436.

No alerts have been found for MDA-MB-436.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 839 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Ancona P, et al. (2026) Diving into AA9-mediated transglutaminase 2 inhibition reveals ferroptosis as driver of anticancer effects. Biochemical pharmacology, 250(Pt 2), 118037.

Pantazaka E, et al. (2026) Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. Oncology research, 34(6), 13.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell, 189(10), 2898.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. International journal of cancer, 156(8), 1606.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. Scientific reports, 15(1), 36766.

Li H, et al. (2025) Mechanistic study of N-acetyltransferase 10 deficiency enhancing olaparib sensitivity in triple negative breast cancer by inhibiting RAD51 N4-acetylcytidine modification. iScience, 28(7), 112860.

Gallo M, et al. (2025) Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites. International journal of molecular sciences, 26(3).

Pinho MP, et al. (2025) Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis. Cell reports. Medicine, 6(8), 102252.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. Cell reports. Medicine, 6(12), 102478.

Wei J, et al. (2025) Protocol to identify small-molecule inhibitors against cancer drug resistance. STAR protocols, 6(1), 103605.

Xu W, et al. (2025) LINC01235 Is an Upstream Regulator of the NFIB Gene and the Notch Pathway in Triple-Negative Breast Cancer. Molecular cancer research : MCR, 23(10), 859.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. Frontiers in oncology, 15, 1549282.

Avellino A, et al. (2025) An Olive Oil-Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer. Cancer research, 85(24), 5015.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell chemical biology.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. Frontiers in immunology, 16, 1539396.

Schwarz E, et al. (2025) Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. Cancer immunology research, 13(4), 560.

Komar ZM, et al. (2025) Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. Cancers, 17(13).

Russo S, et al. (2025) Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. Journal for immunotherapy of cancer, 13(11).